

25 Sep 2023 | Interviews

Insitro's Daphne Koller On The Marriage Of Biology And Machine Learning At The Company's Heart

Instead Of Laying A Single Golden Egg, Insitro Has 'Built A Goose'

by **Chloe Kent**

Industry veteran and serial entrepreneur Daphne Koller tells *In Vivo* about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

[Click here to explore this interactive content online](#) ✨

Citeline · Insitro's Daphne Koller On The Marriage Of Biology And Machine Learning At The Company's Heart

Within the field of artificial intelligence, drug discovery is an area which has some of the greatest potential. *In Vivo* spoke with Daphne Koller, founder and CEO of insitro, about how her company is leveraging machine learning to discover new medicines.

Time stamps:

00.00 Introducing Daphne Koller

06.09 AI's impact on drug discovery

08.26 Why drug discovery?

10.51 How insitro is advancing the field

13.55 AI vs human impact

16.22 Insuring data integrity

<http://invivo.citeline.com/IV148567>

© Citeline 2024. All rights reserved.

19.10 Partnerships in AI drug discovery

21.55 Executive moves into innovative AI

24.40 Life at insitro